PDX INSIGHTS
PIONEERING CANCER RESEARCH
Home
Collections
Bladder
Breast
Leukemia
Liver - Pediatric
Pancreas
Sarcoma
Omics Tools
Management
Data Management
File Management
Drug Studies
Contact Us
Log In
You need to enable JavaScript to run this app page.
Breast
HCI-012
Model Details
Patient
PDX Model
Drug Studies
Histology
Metastasis
Patient Treatment
Patient Information for Model: HCI-012
Contact Model Developer
Model Contact
Model: HCI-012
Model Contact: Alana Welm
Institution: HCI Breast PDX Program
Email:
Alana.Welm@hci.utah.edu
Patient Information
Clinical Timeline
Color Keys:
Positive
Negative
N/A
Clinical Information at Collection
Clinical Biomarkers/Mutations at Collection
Pathology Information at Collection
Model Information for Model: HCI-012
Model Details - Initial Implantation of Patient Tissue
Biomarkers & Mutations
Model Details - Acceptable Conditions for Passaging
Mutations (Cancer Gene Census List)
Mutation data is currently not available.
CNV
There are no omics data for this model.
Drug Studies for Model: HCI-012
Treatment Response Across All Studies
CR <=-95% to -100%
PR <-30% to >-95%
SD >=-30% to +20%
PD >=+20%
NA
Drug Study: Legacy2017
Study Metadata
Study ID:
Legacy2017
Study Type:
Efficacy
Study Description:
Dosing Initiation Timepoint:
Number of Arms:
16
Mouse Strain:
PI:
Alana Welm
Study Title:
Legacy 2017 - PDX Efficacy Study
Treatments:
5-Fluorouracil, MK-1775, Olaparib, Ponatinib, Doxorubicin, AZD8186, Palbociclib, TAK228, Palbociclib+AZD8186, Palbociclib+TAK228, Apitilosib, Everolimus, Gemcitabine, Paclitaxel, Lapatinib
Study Duration:
Transplant Site
Transplant Material:
Study Design
Total arms showing: 6
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Study Description
Arm Type
Treatment Arms
Number of Mice
Dose (mg/kg)
Concentration (mg/ml)
Vehicle
Route
Dosing Schedule
Treatment
TAK228
4
Control
Vehicle
4
Treatment
Palbociclib
6
Treatment
AZD8186
5
Treatment
Palbociclib+TAK228
5
Treatment
Palbociclib+AZD8186
7
Total arms showing: 6
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Treatment Results
Total treatment results showing: 6
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Treatment Arm
Treatment Duration
Monitoring Method
Monitor Duration
Tumor volume over time (%)
Response Category
TAK228
22
83
PD
Vehicle
22
271
PD
Palbociclib
22
117
PD
AZD8186
22
243
PD
Palbociclib+TAK228
22
58
PD
Palbociclib+AZD8186
22
236
PD
Total treatment results showing: 6
F
P
1
N
E
Rows Per Page
10
15
25
50
Download
Histology Information for Model: HCI-012
There are no histology images for this model.
Metastasis Information for Model: HCI-012
Patient
PDX
Abdomen
Adrenal gland
Bone
Bone (de novo)
Bones
Brain
CTC
Chest
Chest wall
Contralateral Breast
Dura
Fallopian Tubes
Head
Kidney
LMD
Liver
Lung
Lymph node
Lymph nodes
Neck
None
Ovary
Pancreas
Pericardium
Peritoneal cavity
Peritoneum
Pleura
Pleural effusion
Shoulder
Skin
Spine
Spleen
Thoracic Spine
Thymus
medistinal and right hilar
Patient Treatment Information for Model: HCI-012
Event Id
Treatment
Treatment Setting
Age at Start
Age at End
Duration
8
Letrozole
Neoadjuvant
48.01
50.25
818 days
9
Abraxane, 5-fluorouracil, Cyclophosphamide, Aldesleukin/Proleukin, Interleukin 2, Epirubicin, Leucovarin, Methotrexate
Neoadjuvant
48.33
50.33
730 days
13
Doxorubicin
Neoadjuvant
50.25
50.33
29 days
14
Capecitabine
Neoadjuvant
50.33
50.41
29 days
15
Herceptin, Vinerolbine
Neoadjuvant
50.25
50.67
153 days
17
Capecitibine/Lapatinab
Neoadjuvant
50.67
50.91
88 days
19
Radiation to the neck and lung
Neoadjuvant
50.91
51.0
33 days
Please wait...
